145 related articles for article (PubMed ID: 28258670)
1. The role of metallothionein in oncogenesis and cancer treatment.
Bizoń A; Jędryczko K; Milnerowicz H
Postepy Hig Med Dosw (Online); 2017 Feb; 71(0):98-109. PubMed ID: 28258670
[TBL] [Abstract][Full Text] [Related]
2. Metallothioneins in human tumors and potential roles in carcinogenesis.
Cherian MG; Jayasurya A; Bay BH
Mutat Res; 2003 Dec; 533(1-2):201-9. PubMed ID: 14643421
[TBL] [Abstract][Full Text] [Related]
3. Role of metallothionein in carcinogenesis.
Cherian MG; Howell SB; Imura N; Klaassen CD; Koropatnick J; Lazo JS; Waalkes MP
Toxicol Appl Pharmacol; 1994 May; 126(1):1-5. PubMed ID: 8184419
[TBL] [Abstract][Full Text] [Related]
4. The role of metallothionein in oncogenesis and cancer prognosis.
Pedersen MØ; Larsen A; Stoltenberg M; Penkowa M
Prog Histochem Cytochem; 2009; 44(1):29-64. PubMed ID: 19348910
[TBL] [Abstract][Full Text] [Related]
5. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs.
Lazo JS; Kuo SM; Woo ES; Pitt BR
Chem Biol Interact; 1998 Apr; 111-112():255-62. PubMed ID: 9679559
[TBL] [Abstract][Full Text] [Related]
6. Metallothionein isoforms as double agents - Their roles in carcinogenesis, cancer progression and chemoresistance.
Merlos Rodrigo MA; Jimenez Jimemez AM; Haddad Y; Bodoor K; Adam P; Krizkova S; Heger Z; Adam V
Drug Resist Updat; 2020 Sep; 52():100691. PubMed ID: 32615524
[TBL] [Abstract][Full Text] [Related]
7. Metallothionein: a multifunctional protein from toxicity to cancer.
Theocharis SE; Margeli AP; Koutselinis A
Int J Biol Markers; 2003; 18(3):162-9. PubMed ID: 14535585
[TBL] [Abstract][Full Text] [Related]
8. Protective function of metallothionein against certain anticancer agents.
Endresen L; Rugstad HE
Experientia Suppl; 1987; 52():595-602. PubMed ID: 2959550
[TBL] [Abstract][Full Text] [Related]
9. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
10. Targeting metallothionein for prognosis and treatment of breast cancer.
Lai Y; Yip GW; Bay BH
Recent Pat Anticancer Drug Discov; 2011 May; 6(2):178-85. PubMed ID: 21449882
[TBL] [Abstract][Full Text] [Related]
11. [Metallothionein and cancer].
Li X; Ru B
Wei Sheng Yan Jiu; 1999 May; 28(3):185-7. PubMed ID: 12712730
[TBL] [Abstract][Full Text] [Related]
12. The roles of metallothioneins in carcinogenesis.
Si M; Lang J
J Hematol Oncol; 2018 Aug; 11(1):107. PubMed ID: 30139373
[TBL] [Abstract][Full Text] [Related]
13. Metallothionein and anticancer agents: the role of metallothionein in cancer chemotherapy.
Doz F; Roosen N; Rosenblum ML
J Neurooncol; 1993 Aug; 17(2):123-9. PubMed ID: 8145055
[TBL] [Abstract][Full Text] [Related]
14. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices.
Ioachim EE; Charchanti AV; Stavropoulos NE; Athanassiou ED; Michael MC; Agnantis NJ
Anticancer Res; 2001; 21(3B):1757-61. PubMed ID: 11497256
[TBL] [Abstract][Full Text] [Related]
15. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals.
Sato M; Kondoh M
Tohoku J Exp Med; 2002 Jan; 196(1):9-22. PubMed ID: 12498322
[TBL] [Abstract][Full Text] [Related]
16. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of metallothionein in human gastrointestinal cancer.
Janssen AM; van Duijn W; Kubben FJ; Griffioen G; Lamers CB; van Krieken JH; van de Velde CJ; Verspaget HW
Clin Cancer Res; 2002 Jun; 8(6):1889-96. PubMed ID: 12060633
[TBL] [Abstract][Full Text] [Related]
18. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.
Surowiak P; Materna V; Maciejczyk A; Pudełko M; Markwitz E; Spaczyński M; Dietel M; Zabel M; Lage H
Virchows Arch; 2007 Mar; 450(3):279-85. PubMed ID: 17235562
[TBL] [Abstract][Full Text] [Related]
19. Correlation between expression of metallothionein and expression of Ki-67 and MCM-2 proliferation markers in non-small cell lung cancer.
Werynska B; Pula B; Muszczynska-Bernhard B; Piotrowska A; Jethon A; Podhorska-Okolow M; Dziegiel P; Jankowska R
Anticancer Res; 2011 Sep; 31(9):2833-9. PubMed ID: 21868526
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents.
Endo T; Yoshikawa M; Ebara M; Kato K; Sunaga M; Fukuda H; Hayasaka A; Kondo F; Sugiura N; Saisho H
J Gastroenterol; 2004 Dec; 39(12):1196-201. PubMed ID: 15622485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
